MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:41Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Corticosteroids]]
			[[Category:Glucocorticoids]]
			[[Category:Topical corticosteroids]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #280

2026-05-23T04:08:52Z

parser-claude batch MedTemplate pre-fill, Top 300 #280

New page

{{MedTemplate
| generic = Betamethasone (valerate, dipropionate, sodium phosphate, acetate)
| brand = Celestone (oral/injectable), Diprolene/Diprosone (topical), Luxiq (foam), Celestone Soluspan (depot IM)
| structure =
| classes = [[:Category:Corticosteroids|Corticosteroid]], [[:Category:Glucocorticoids|Glucocorticoid (long-acting, high-potency)]], [[:Category:Topical_corticosteroids|Topical corticosteroid (high-to-super-high potency depending on ester)]]
| uses = <vote slug="antenatal-lung-maturation-use">Antenatal lung maturation (24-34 weeks gestation)</vote>, <vote slug="severe-dermatitis-use">Severe corticosteroid-responsive dermatoses (topical)</vote>, <vote slug="intra-articular-arthritis-use">Intra-articular and soft-tissue injection</vote>, <vote slug="autoimmune-flare-use">Autoimmune disease flare (oral)</vote>
| starting_dose = Antenatal: Celestone Soluspan 12 mg IM q24h × 2 doses; topical: pea-sized amount BID; intra-articular varies by joint
| preparations = 0.6 mg/5 mL oral solution; Celestone Soluspan 6 mg/mL IM/IA (mix of sodium phosphate + acetate); 0.05% and 0.1% topical cream/ointment/lotion/foam (various salts); augmented betamethasone 0.05% (super-high potency)
| fda_max = Indication-specific
| pill_id =
| routes = Oral, IM, IA, topical
| onset = Hours
| duration = Biologic 36-54 hours (long-acting)
| halflife = Plasma ~5 hours; biologic ~36-54 hours<ref name="celestone-label">FDA Prescribing Information, Celestone Soluspan (betamethasone sodium phosphate/acetate), Organon, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/014602s086lbl.pdf</ref>
| bioavailability = Oral ~70%; depot IM provides sustained release over weeks<ref name="celestone-label" />
| pregnancy = Antenatal use (12 mg IM × 2 doses 24h apart) is one of the most evidence-based interventions in obstetrics — reduces neonatal respiratory distress syndrome and mortality in threatened preterm delivery between 24 and 34 weeks. Other uses weigh benefit against fetal HPA suppression.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="betamethasone-mech-claim">Betamethasone is a synthetic fluorinated glucocorticoid (the 9α-fluoro group enhances activity), structurally similar to dexamethasone with ~25× the potency of hydrocortisone, virtually no mineralocorticoid activity, and one of the longest biologic half-lives in routine use.</vote> Activates the glucocorticoid receptor to broadly remodel inflammatory, immune, and metabolic transcription. The dipropionate, valerate, and augmented dipropionate ester forms determine topical potency (high to super-high)<ref name="celestone-label" />.
}}

== References ==
<references />

Betamethasone - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #280